SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion is highly fragmented, with participants primarily debating political, social, and geopolitical controversies surrounding the company's namesake and his administration rather than focusing on specific financial or business catalysts. The most common themes include reactions to the U.S.-Iran conflict, ongoing trade tensions with Canada, and criticism of the company's leadership.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Investors are intensely focused on the delayed topline results of the phase 3 REGAL trial for GPS, with discussion centering on the clinical implications of the extended trial duration and whether the long-tail survival indicates superior efficacy or trial design variables. The community remains divided, with long-term investors pointing to trial management and potential buyout interest, while others express caution regarding legal investigations and the lack of official event-milestone confirmation.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending as investors rotate into the nuclear energy sector, fueled by growing electricity demand from AI data centers and ongoing industry developments. While some traders remain optimistic about the company's long-term potential as a small modular reactor provider, others express frustration over the lack of near-term commercial contracts and recent financial results.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is trending primarily due to community optimism following strong quarterly earnings, which highlighted robust performance across its drug portfolio and increased sales guidance. Traders are also closely monitoring the company's progress on late-stage trials for its obesity drug, MariTide, as a key catalyst for future growth.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending following mixed Q1 earnings results, where a slight revenue miss was overshadowed by a robust earnings beat, strong order guidance, and sustained confidence in the company's margin expansion and platform growth. Despite the positive market reaction to the outlook, investor debate persists regarding the stock's premium valuation and the sustainability of its growth model in a challenging economic environment.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing heightened investor attention as traders speculate on potential regulatory developments and prospective ETF launches, while the community remains divided over the impact of token emissions and leadership's role in price performance. Sentiment is mixed, with some participants expressing frustration over past volatility and dilution concerns, while others view current price levels as an accumulation opportunity tied to recent institutional interest.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores is receiving attention following a fiscal first-quarter earnings report that featured a double-line beat, though shares declined as investors reacted to stagnant annual guidance and concerns regarding slowing comparable-store sales growth. The community remains divided between long-term investors highlighting the company's defensive business model and profitable convenience-store operations versus traders focused on the recent selloff and potential overvaluation.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as market participants debate the stock's valuation and outlook ahead of upcoming quarterly earnings. While some traders express bearishness regarding macro pressures on consumer spending and the stock's long-term downtrend, others identify it as an oversold opportunity driven by strong autoship retention and institutional ownership.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as traders react to a formal proposal for a native decentralized stablecoin and recent shifts in tokenomics, sparking debate over its long-term potential versus concerns about persistent price declines. While some investors remain bullish on its underlying technology and staking rewards, others criticize its performance and market sentiment as fragmented.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is trending as traders react to a new $100 million bank guarantee that strengthens the company's liquidity and supports the acceleration of its Phase 2 expansion. While the stock has seen significant volatility, the community is divided between bullish sentiment regarding the company's production execution and ongoing skepticism from those concerned about historical price manipulation and the stock's tendency to reverse gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.

Futures Flat Ahead Of Key PCE Report, Nvidia Earnings

Futures Flat Ahead Of Key PCE Report, Nvidia Earnings

 Stock futures are are flat and Treasuries slipped while oil stumbled heading into today's PCE report and NVDA earnings. As of 8:00am ET, S&P Futures are unchanged and Nasdaq futures drop 0.2% as?NVDA and MRVL both rise 0.2% with...

Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?

Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.

Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.

SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?

Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.

SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses

Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel investor optimism and lift the stock.

Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today

SYRE has surged on pipeline progress and a strong cash position, but with no product revenue and key trial data still ahead, is the risk already priced in?

SYRE and Spyre Ride New IBD Trends in Biotech Drug Design

SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.

Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts

The investment case for Spyre Therapeutics is built around a straightforward but high-risk question: can its broad IBD pipeline produce meaningful clinical proof-of-concept data? 

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

SYRE Stock Marks Best Session In About 3 Years — Here’s Why 

Equity

Bearish Sentiment

Yes, hike is locked in

No, inflation data still matters more

Fed stays on hold anyway

Too early to tell

August nonfarm payrolls surged by 162,000, nearly triple the 53,000-56,000 consensus estimate and the strongest monthly gain since March, while unemployment held steady at 4.1%, adding fuel to the case for a Federal Reserve rate hike at its September meeting. Does this jobs report cement a September rate hike? Vote and explain your reasoning in the comments.

August nonfarm payrolls surged 162,000, nearly triple estimates, while unemployment held at 4.1%. Does this cement a September rate hike?

Current Price	$90.79
Prev Close	$88.98
Open	$85.00
Dividend Yield	0.00%
50-Day Moving Average	$98.13
Beta	1.69
Avg. Volume	1.01M
PE Ratio	-41.65

52-Week High	$110.18
52-Week Low	$14.51
Market Capitalization	$7.85B
EPS (Annual)	-$1.98
Price to Book	8.37
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SYRE Fundamentals